menu
    • menu

    Company profile for MediWound

    NEW Drugs in Dev: 3
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MediWound Ltd. is a biotechnology niche specialty company. Established in 2001, MediWound is focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management. MediWound’s goal is to provide healthcare professionals and patients with its innovative, burn wound eschar removal agent, NexoBrid™. NexoBrid™, is indicated in ...
    MediWound Ltd. is a biotechnology niche specialty company. Established in 2001, MediWound is focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management. MediWound’s goal is to provide healthcare professionals and patients with its innovative, burn wound eschar removal agent, NexoBrid™. NexoBrid™, is indicated in Europe for removal of eschar in adults with deep partial- and full-thickness thermal burns. NexoBrid™ successfully completed clinical development in hospitalized burn wounds and was launched throughout Europe.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MediWoundIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    42 Hayarkon Street, Yavne
    Telephone
    Telephone
    +972 77 9714100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mediwound.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/mediwound
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    German Wound Congress

    German Wound Congress

    Not Confirmed

    envelop Contact Supplier

    German Wound Congress

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    U.S. Consensus Backs MediWound's Chronic Wound Strategy
    U.S. Consensus Backs MediWound's Chronic Wound Strategy

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272390/30505/en/Newly-Published-U-S-Expert-Consensus-Aligns-with-MediWound-s-Strategy-for-Chronic-Wound-Debridement.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    Mediwound To Unveil Escharex Data At Wound Care Conferences
    Mediwound To Unveil Escharex Data At Wound Care Conferences

    07 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/07/3268949/30505/en/MediWound-to-Present-New-EscharEx-Data-at-Leading-Wound-Care-Conferences.html

    GLOBENEWSWIRE
    07 Apr 2026
    Share Share
    MediWound Reports BARDA Grants Vericel $197M for NexoBrid
    MediWound Reports BARDA Grants Vericel $197M for NexoBrid

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267793/30505/en/MediWound-Reports-BARDA-Contract-Award-to-Vericel-for-NexoBrid-Valued-at-up-to-197-Million.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    MediWound Reports Q4 and Full Year 2025 Financial Results
    MediWound Reports Q4 and Full Year 2025 Financial Results

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250013/30505/en/MediWound-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    Mediwound Files Annual Report On Form 20-F
    Mediwound Files Annual Report On Form 20-F

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250703/30505/en/MediWound-Files-Annual-Report-on-Form-20-F.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share
    MediWound To Release 2025 Q4 & Full-Year Financial Result
    MediWound To Release 2025 Q4 & Full-Year Financial Result

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3241048/30505/en/MediWound-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search